EP Patent

EP3080152A1 — Non-acylated exendin-4 peptide analogues

Assigned to Sanofi SA · Expires 2016-10-19 · 10y expired

What this patent protects

The present invention relates to exendin-4 derivatives and their medical use, for example in the treatment of disorders of the metabolic syndrome, including diabetes and obesity, as well as reduction of excess food intake.

USPTO Abstract

The present invention relates to exendin-4 derivatives and their medical use, for example in the treatment of disorders of the metabolic syndrome, including diabetes and obesity, as well as reduction of excess food intake.

Drugs covered by this patent

Patent Metadata

Patent number
EP3080152A1
Jurisdiction
EP
Classification
—
Expires
2016-10-19
Drug substance claim
No
Drug product claim
No
Assignee
Sanofi SA
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.